Related Experiment Video
Updated: Mar 18, 2026
07:47
Author Spotlight: Unveiling Transmembrane Protein Family-Related Markers in Gastric Cancer and Implications for Targeted Therapies
Published on: September 15, 2023
2.3K
TMPRSS4 as an emerging potential poor prognostic factor for solid tumors: A systematic review and meta-analysis
Ping Zeng1, Peng Zhang2, Li-Na Zhou1
1Department of Radiotherapy and Oncology, Kunshan First People's Hospital Affiliated to Jiangsu University, Kunshan, Jiangsu Province, China.
Oncotarget
|June 27, 2016
Summary
High transmembrane protease serine 4 (TMPRSS4) expression in solid tumors is linked to poorer patient outcomes. This finding suggests TMPRSS4 may serve as a prognostic biomarker or therapeutic target.
Area of Science:
- Oncology
- Molecular Biology
- Biomarker Research
Background:
- The prognostic significance of transmembrane protease serine 4 (TMPRSS4) in solid tumors remains unclear.
- Existing studies on TMPRSS4's role in cancer prognosis have yielded inconclusive results.
- There is a need to consolidate evidence regarding TMPRSS4 as a prognostic indicator in solid tumors.
Purpose of the Study:
- To conduct a meta-analysis to clarify the prognostic value of transmembrane protease serine 4 (TMPRSS4) in solid tumors.
- To evaluate the association between TMPRSS4 expression and patient outcomes, including overall survival (OS) and time to tumor progression (TTP).
- To investigate potential regional differences in the prognostic impact of TMPRSS4.
Main Methods:
- A systematic literature search was performed across PubMed, Web of Science, and Embase databases.
- Twelve studies comprising 1,955 participants were included in the meta-analysis.
- Primary outcome endpoints were overall survival (OS) and time to tumor progression (TTP).
Main Results:
- High TMPRSS4 expression in tumor tissues was significantly associated with poorer overall survival (pooled HR = 2.981, P < 0.001).
- Elevated TMPRSS4 levels correlated with shorter time to tumor progression (pooled HR = 2.456, P < 0.001).
- Subgroup analysis indicated a significant association between TMPRSS4 and prognosis within the China region.
Conclusions:
- Overexpression of TMPRSS4 in solid tumors is significantly linked to poor patient prognosis.
- TMPRSS4 demonstrates potential as a valuable prognostic biomarker for solid tumors.
- TMPRSS4 represents a promising therapeutic target for solid tumor management.
Related Concept Videos
02:07Tumor Progression
7.8K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
7.8K
02:07Tumor Progression
3.5K
3.5K
03:03mTOR Signaling and Cancer Progression
5.0K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
5.0K